Jazz Pharmaceuticals plc
NASDAQ · JAZZ·Dublin, Ireland·Mid-cap·Approved
Neuroscience and oncology company with Xywav/Xyrem franchise in narcolepsy and idiopathic hypersomnia and Rylaze in ALL. Jazz's pipeline includes zanidatamab (HER2 bispecific) for GI cancers and suvecaltamide for essential tremor, diversifying across sleep and hematologic malignancies.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Jazz Pharmaceuticals Corporate Overview | Corporate overview | January 1, 2026 | 42 |